Tacrolimus placental transfer at delivery and neonatal exposure through breast milk

British Journal of Clinical Pharmacology

Volumn 76, Issue 6, 2013, Pages 988-996

  Zheng, Songmao ^a   Easterling, Thomas R ^a   Hays, Karen ^a   Umans, Jason G ^b,c,d   Miodovnik, Menachem ^b,c   Clark, Shannon ^e   Calamia, Justina C ^a   Thummel, Kenneth E ^a   Shen, Danny D ^a   Davis, Connie L ^a   Hebert, Mary F ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MEDSTAR HEALTH RESEARCH INSTITUTE   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d Delaware   (United States)

^e University of Texas Medical Branch School of Medicine   (United States)

Author keywords

breast milk; neonatal exposure; placental transfer; pregnancy; tacrolimus; unbound drug concentration

Indexed keywords

DRUG METABOLITE; TACROLIMUS;

ADULT; ALLOGRAFT; AREA UNDER THE CURVE; ARTICLE; BREAST MILK; CLINICAL ARTICLE; DELIVERY; DRUG BLOOD LEVEL; DRUG EXCRETION; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; HUMAN TISSUE; LIMIT OF QUANTITATION; MATERNAL BLOOD; MATERNAL PLASMA; PERINATAL DRUG EXPOSURE; PLACENTAL TRANSFER; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; UMBILICAL CORD BLOOD;

BREAST MILK; NEONATAL EXPOSURE; PLACENTAL TRANSFER; PREGNANCY; TACROLIMUS; UNBOUND DRUG CONCENTRATION;

ADULT; BREAST FEEDING; DELIVERY, OBSTETRIC; FEMALE; FETAL BLOOD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; MILK, HUMAN; ORGAN TRANSPLANTATION; PLACENTA; PLACENTAL CIRCULATION; PREGNANCY; TACROLIMUS;

EID: 84876289734     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12122     Document Type: Article

References (57)

1. Scott LJ, McKeage K, Keam SJ, Plosker GL,. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247-1297.
2. Jain A, Venkataramanan R, Fung JJ, Gartner JC, Lever J, Balan V, Warty V, Starzl TE,. Pregnancy after liver transplantation under tacrolimus. Transplantation 1997; 64: 559-565.
3. Kainz A, Harabacz I, Cowlrick IS, Gadgil S, Hagiwara D,. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl Int 2000; 13: (Suppl. 1): S299-300.
4. McKay DB, Josephson MA,. Pregnancy in recipients of solid organs-effects on mother and child. N Engl J Med 2006; 354: 1281-1293.
5. French AE, Soldin SJ, Soldin OP, Koren G,. Milk transfer and neonatal safety of tacrolimus. Ann Pharmacother 2003; 37: 815-818.
6. Borrows R, Chusney G, Loucaidou M, James A, Goel S, Borrows S, Van Tromp J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D,. Analysis of factors influencing tacrolimus levels and immunoassay bias in renal transplantation. J Clin Pharmacol 2007; 47: 1035-1042.
7. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T,. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077-6080.
8. Wang JS, Newport DJ, Stowe ZN, Donovan JL, Pennell PB, DeVane CL,. The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient. Drug Metab Rev 2007; 39: 723-746.
9. Hutson JR, Garcia-Bournissen F, Davis A, Koren G,. The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs. Clin Pharmacol Ther 2011; 90: 67-76.
10. Piekoszewski W, Jusko WJ,. Plasma protein binding of tacrolimus in humans. J Pharm Sci 1993; 82: 340-341.
11. Weiss HM, Fresneau M, Moenius T, Stuetz A, Billich A,. Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Drug Metab Dispos 2008; 36: 1812-1818.
12. Zheng S, Easterling TR, Umans JG, Miodovnik M, Calamia JC, Thummel KE, Shen DD, Davis CL, Hebert MF,. Pharmacokinetics of tacrolimus during pregnancy. Ther Drug Monit 2012; 34: 660-670.
13. Sam WJ, Tham LS, Holmes MJ, Aw M, Quak SH, Lee KH, Lim SG, Prabhakaran K, Chan SY, Ho PC,. Population pharmacokinetics of tacrolimus in whole blood and plasma in Asian liver transplant patients. Clin Pharmacokinet 2006; 45: 59-75.
14. Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, Lin YS, Shen DD, Thummel KE,. Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition. Clin Pharmacol Ther 2012; 92: 737-745.
15. Hebert MF, Zheng S, Hays K, Shen DD, Davis CL, Umans JG, Miodovnik M, Thummel KE, Easterling TR,. Interpreting tacrolimus concentrations during pregnancy and postpartum. Transplantation 2012; 95: 908-915.
16. Bramham K, Chusney G, Lee J, Lightstone L, Nelson-Piercy C,. Breastfeeding and tacrolimus: serial monitoring in breast-fed and bottle-fed infants. Clin J Am Soc Nephrol 2013; 8: 563-567.
17. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P,. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147-154.
18. Kamdem LK, Streit F, Zanger UM, Brockmoller J, Oellerich M, Armstrong VW, Wojnowski L,. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 2005; 51: 1374-1381.
19. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, Thummel KE,. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34: 836-847.
20. Rodriguez-Antona C, Jande M, Rane A, Ingelman-Sundberg M,. Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin Pharmacol Ther 2005; 77: 259-270.
21. PROGRAF® product labeling. Astellas Pharma US, Inc. 2009. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/050708s027, 050709s021lbl.pdf (last accessed 12 April 2013).
22. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF,. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41-49.
23. Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I,. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999; 39: 91-96.
24. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN,. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 37: 485-505.
25. Gardiner SJ, Begg EJ,. Breastfeeding during tacrolimus therapy. Obstet Gynecol 2006; 107: 453-455.
26. Koshimichi H, Ito K, Hisaka A, Honma M, Suzuki H,. Analysis and prediction of drug transfer into human milk taking into consideration secretion and reuptake clearances across the mammary epithelia. Drug Metab Dispos 2011; 39: 2370-2380.
27. Chen YL, Hirabayashi H, Akhtar S, Pelzer M, Kobayashi M,. Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 830: 330-341.
28. Nakai D, Kumamoto K, Sakikawa C, Kosaka T, Tokui T,. Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method. J Pharm Sci 2004; 93: 847-854.
29. Hinderling PH,. Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 1997; 49: 279-295.
30. Jahazi A, Kordi M, Mirbehbahani NB, Mazloom SR,. The effect of early and late umbilical cord clamping on neonatal hematocrit. J Perinatol 2008; 28: 523-525.
31. Danesi R, Del Tacca M,. Teratogenesis and immunosuppressive treatment. Transplant Proc 2004; 36: 705-707.
32. McKay DB, Josephson MA,. Pregnancy after kidney transplantation. Clin J Am Soc Nephrol 2008; 3: S117-125.
33. Coscia LA, Constantinescu S, Moritz MJ, Frank AM, Ramirez CB, Maley WR, Doria C, McGrory CH, Armenti VT,. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 2010; 65-85.
34. Humphreys RA, Wong HH, Milner R, Matsuda-Abedini M,. Pregnancy outcomes among solid organ transplant recipients in British Columbia. J Obstet Gynaecol Can 2012; 34: 416-424.
35. Jain AB, Reyes J, Marcos A, Mazariegos G, Eghtesad B, Fontes PA, Cacciarelli TV, Marsh JW, de Vera ME, Rafail A, Starzl TE, Fung JJ,. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation 2003; 76: 827-832.
36. Audus KL,. Controlling drug delivery across the placenta. Eur J Pharm Sci 1999; 8: 161-165.
37. Bourget P, Fernandez H, Bismuth H, Papiernik E,. Transplacental passage of cyclosporine after liver transplantation. Transplantation 1990; 49: 663.
38. Venkataramanan R, Koneru B, Wang CC, Burckart GJ, Caritis SN, Starzl TE,. Cyclosporine and its metabolites in mother and baby. Transplantation 1988; 46: 468-469.
39. Flechner SM, Katz AR, Rogers AJ, Van Buren C, Kahan BD,. The presence of cyclosporine in body tissues and fluids during pregnancy. Am J Kidney Dis 1985; 5: 60-63.
40. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W,. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta 2006; 27: 602-609.
41. Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ,. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol 2004; 57: 298-309.
42. D'Arena G, Musto P, Cascavilla N, Di Giorgio G, Fusilli S, Zendoli F, Carotenuto M,. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features. Haematologica 1998; 83: 197-203.
43. Milman N, Bergholt T, Byg KE, Eriksen L, Graudal N,. Iron status and iron balance during pregnancy. A critical reappraisal of iron supplementation. Acta Obstet Gynecol Scand 1999; 78: 749-757.
44. Christians U, Jacobsen W, Benet LZ, Lampen A,. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41: 813-851.
45. Kelly PA, Burckart GJ, Venkataramanan R,. Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm 1995; 52: 1521-1535.
46. Ichimaru N, Takahara S, Kokado Y, Wang JD, Hatori M, Kameoka H, Inoue T, Okuyama A,. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001; 158: 417-423.
47. Minematsu T, Sugiyama E, Kusama M, Hori S, Yamada Y, Ohtani H, Sawada Y, Sato H, Takayama T, Sugawara Y, Makuuchi M, Iga T,. Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients. Transplant Proc 2004; 36: 1506-1511.
48. Ahmed M, Venkataraman R, Logar AJ, Rao AS, Bartley GP, Robert K, Dodson FS, Shapiro R, Fung JJ, Zeevi A,. Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. Ther Drug Monit 2001; 23: 354-362.
49. Hill MD, Abramson FP,. The significance of plasma-protein binding on the fetal maternal distribution of drugs at steady-state. Clin Pharmacokinet 1988; 14: 156-170.
50. Krauer B, Dayer P, Anner R,. Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs. Br J Obstet Gynaecol 1984; 91: 875-881.
51. Armenti VT, Radomski JS, Moritz MJ, Gaughan WJ, McGrory CH, Coscia LA,. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 2003; 131-141.
52. Breedveld P, Beijnen JH, Schellens JHM,. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006; 27: 17-24.
53. Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, Schinkel AH,. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 2005; 11: 127-129.
54. Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, Mao Q,. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 2006; 58: 374-383.
55. Alcorn J, Lu X, Moscow JA, McNamara PJ,. Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction. J Pharmacol Exp Ther 2002; 303: 487-496.
56. Ito S, Alcorn J,. Xenobiotic transporter expression and function in the human mammary gland. Adv Drug Deliv Rev 2003; 55: 653-665.
57. Edwards JE, Alcorn J, Savolainen J, Anderson BD, McNamara PJ,. Role of P-glycoprotein in distribution of nelfinavir across the blood-mammary tissue barrier and blood-brain barrier. Antimicrob Agents Chemother 2005; 49: 1626-1628.